Free Trial

hVIVO (LON:HVO) Share Price Passes Below 50-Day Moving Average - Should You Sell?

hVIVO logo with Medical background

Key Points

  • hVIVO plc's stock price dropped below its 50-day moving average of GBX 11.24, trading as low as GBX 9.50 during recent sessions.
  • Equities analysts remain optimistic, with Shore Capital issuing a "buy" rating and a target price of GBX 35, while Peel Hunt set a target of GBX 21.
  • The company specializes in contract research and human challenge clinical trials, working with major pharmaceutical and public health organizations to test vaccines and antivirals.
  • Looking to Export and Analyze hVIVO Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

hVIVO plc (LON:HVO - Get Free Report)'s share price crossed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 11.24 ($0.15) and traded as low as GBX 9.50 ($0.13). hVIVO shares last traded at GBX 10.50 ($0.14), with a volume of 3,685,997 shares.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HVO. Peel Hunt reissued an "add" rating and issued a GBX 21 ($0.28) target price on shares of hVIVO in a research note on Tuesday, July 29th. Shore Capital reiterated a "buy" rating and issued a GBX 35 ($0.46) price objective on shares of hVIVO in a report on Tuesday, July 22nd.

Check Out Our Latest Stock Analysis on HVO

hVIVO Trading Down 5.0%

The stock's 50-day simple moving average is GBX 10.96 and its two-hundred day simple moving average is GBX 14.84. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm has a market capitalization of £67.22 million, a P/E ratio of 3.92 and a beta of 0.97.

About hVIVO

(Get Free Report)

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

Read More

Should You Invest $1,000 in hVIVO Right Now?

Before you consider hVIVO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.

While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk
3 Overlooked AI Stocks That Chipmakers Can’t Live Without

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines